CN106266334A - A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application - Google Patents
A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application Download PDFInfo
- Publication number
- CN106266334A CN106266334A CN201610950646.5A CN201610950646A CN106266334A CN 106266334 A CN106266334 A CN 106266334A CN 201610950646 A CN201610950646 A CN 201610950646A CN 106266334 A CN106266334 A CN 106266334A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- rhizoma atractylodis
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/08—Devices for applying needles to such points, i.e. for acupuncture ; Acupuncture needles or accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Rehabilitation Therapy (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine composition treating fat concurrent hyperlipemia, described Chinese medicine composition is made up of the crude drug of following weight portion: the Radix Astragali 20 30 parts, Radix Stephaniae Tetrandrae 5 15 parts, Rhizoma Atractylodis 5 15 parts, the Rhizoma Atractylodis Macrocephalae 5 15 parts, 10 20 parts of Poria, Rhizoma Alismatis 10 20 parts, Semen Plantaginis 15 25 parts, Ramulus Cinnamomi 15 25 parts, 1 10 parts of Radix Glycyrrhizae, Semen Raphani 10 20 parts, Fructus Crataegi 10 20 parts, Semen Cassiae 5 15 parts.The invention still further relates to the application in the fat concurrent hyperlipidemia of above-mentioned Chinese medicine composition acupuncture and drugs preparation treatment.The Chinese medicine composition acupuncture and drugs group of the present invention can significantly improve the therapeutic effect of the fat concurrent hyperlipemia Splenic asthenia and obstruction of dampness for the treatment of based on acupuncture, and can significantly improve the sings and symptoms of patient, has a good application prospect.
Description
Technical field
The present invention relates to technical field of Chinese medicines, specifically, be a kind of Chinese medicine composition treating fat concurrent hyperlipemia
Thing and acupuncture and drugs application.
Background technology
Along with raising and the change of dietary habit of people's living standard, obesity day by day becomes common frequently-occurring disease, single
Pure property obesity is metabolic disease that is too much because taking in heat, that cause in causing athero body, is often accompanied by again other metabolism
Property disease, such as hyperlipidemia, hypertension, diabetes etc..Simple obesity complicated hyperlipemia refers to cause with obesity for inducement
In blood plasma or serum, triacylglycerol, T-CHOL, low density lipoprotein, LDL raise, and high density lipoprotein is low, show as high gallbladder solid
The metabolism disorder of blood lipid syndrome of alcoholemia, hypertriglyceridemia or combined hyperlipidemia.Hyperlipoproteinemia is the most generally
Described hyperlipemia, refers to that serum lipoprotein concentration abnormality raises, can be classified as simply: hypercholesterolemia, height
Triglyceride, combined hyperlipidemia familial and Low high-density lipoprotein cholesterol；Can be divided into again by the cause of disease: constitutional is high
Lipidemia and Secondary Hyperlipidemia.Cardiovascular disease is gradually increased at the sickness rate of China.Hypercholesterolemia, hypertension,
Smoking is listed in coronary heart disease Major Risk Factors.Increasing for a long time with cholesterolemia, the incidence rate of coronary event increases, by blood
Cholesterol long-term control, in proper level, is possible not only to prevention of arterial atherosis, and can alleviate atherosclerotic plaque, subtracts
Few coronary event.In recent years, the understanding of hypertriglyceridemia meaning in atherosclerosis is deepened.Cause
This, the preventing and treating carrying out hyperlipemia in many people becomes the important step of atherosclerosis preventing and treating.Reasonably diet with
Life regulation is particularly important to preventing and treating hyperlipemia.Lipid-regulation medicine can partly be kept on a diet and be treated out of contior hyperlipemia
Disease.
Disclose document " warming needle moxibustion associating auricular acupuncture treatment spleen asthenia and dampness retention periodical " world Chinese digests magazine " in August, 2015
The fat concurrent hyperlipidemia patient clinical efficacy of type ", it uses warming needle moxibustion, ear acupuncture to combine and treats the fat concurrent height of Splenic asthenia and obstruction of dampness
Lipidemia patient, result shows: warming needle moxibustion associating ear acupuncture and the fat concurrent hyperlipemia of simple Treated by Warm Acupuncture Splenic asthenia and obstruction of dampness
Good efficacy, warming needle moxibustion associating auriculotherapy is all had to be better than simple warming needle moxibustion therapy for the optimum adjustment of lipid metabolism, can show
Write the clinical symptoms improving patient.Chinese patent CN02159229.2, discloses the Chinese medicine preparation of a kind of Weight-reducing and lipid-lowering, by following
The medicament that parts by weight raw material is made: Radix Stephaniae Tetrandrae 45-85 part, Rhizoma Alismatis 80-120 part, Semen Sinapis Albae 30-70 part, Semen Persicae 30-70 part, winter
Melon skin 80-120 part, Folium Nelumbinis 80-120 part, Radix Ginseng 5-45 part, Rhizoma Atractylodis 30-70 part, Radix Et Rhizoma Rhei 7.5-47.5 part, Rhizoma Atractylodis Macrocephalae 30-70 part,
Radix Astragali 80-120 part, Pericarpium Citri Reticulatae 20-60 part, Fructus Amomi Rotundus 10-50 part, Rhizoma Polygonati Odorati 80-120 part, Pollen Tyjphae 4.5-10.5 part, Fructus Gleditsia 90-
130 parts；This Chinese medicine preparation has and significantly reduces blood fat, abdomen fat, sebum and reduction abdomen circle, hip circumference, bluntness, the work of Body Mass Index
With, and hyperlipemia, fatty liver are had significant curative effect.But in prior art, fat concurrent about present invention treatment
The Chinese medicine composition of hyperlipemia and acupuncture and drugs application, yet there are no report.
Summary of the invention
First purpose of the present invention is for deficiency of the prior art, it is provided that one treats fat concurrent hyperlipemia
Chinese medicine composition.
Second object of the present invention is to provide the purposes of Chinese medicine composition described above.
It is fat concurrent high that third object of the present invention is to provide Chinese medicine composition acupuncture and drugs described above preparation treatment
Application in lipidemia medicine.
For achieving the above object, the present invention adopts the technical scheme that:
A kind of Chinese medicine composition treating fat concurrent hyperlipemia, described Chinese medicine composition is former by following weight portion
Material medicine is made: Radix Astragali 20-30 part, Radix Stephaniae Tetrandrae 5-15 part, Rhizoma Atractylodis 5-15 part, Rhizoma Atractylodis Macrocephalae 5-15 part, Poria 10-20 part, Rhizoma Alismatis 10-20
Part, Semen Plantaginis 15-25 part, Ramulus Cinnamomi 15-25 part, Radix Glycyrrhizae 1-10 part, Semen Raphani 10-20 part, Fructus Crataegi 10-20 part, Semen Cassiae 5-
15 parts.
Further, described Chinese medicine composition is made up of the crude drug of following weight portion: Radix Astragali 22-28 part, Radix Stephaniae Tetrandrae 7-13
Part, Rhizoma Atractylodis 7-13 part, Rhizoma Atractylodis Macrocephalae 7-13 part, Poria 13-17 part, Rhizoma Alismatis 13-17 part, Semen Plantaginis 17-23 part, Ramulus Cinnamomi 17-23 part, sweet
Grass 3-7 part, Semen Raphani 13-17 part, Fructus Crataegi 13-17 part, Semen Cassiae 7-13 part.
Further, described Chinese medicine composition is made up of the crude drug of following weight portion: the Radix Astragali 25 parts, Radix Stephaniae Tetrandrae 10 parts, grey
Art 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, 15 parts of Poria, Rhizoma Alismatis 15 parts, Semen Plantaginis 20 parts, Ramulus Cinnamomi 20 parts, 5 parts of Radix Glycyrrhizae, Semen Raphani 15 parts, raw mountain
Short, bristly hair or beard 15 parts, Semen Cassiae 10 parts.
For realizing above-mentioned second purpose, the present invention adopts the technical scheme that:
The purposes of arbitrary described Chinese medicine composition, answering in the medicine preparing the fat concurrent hyperlipemia for the treatment of
With.
Further, described fat Chinese medical discrimination belongs to Splenic asthenia and obstruction of dampness.
Further, described medicine adds pharmaceutically acceptable carrier as required and is prepared as any pharmaceutical dosage form.
Further, described medicine also includes the adjuvant pharmaceutically allowed.
Further, the dosage form of described medicine is capsule, granule, tablet, oral liquid, mixture or syrup.
Further, described pharmaceutically acceptable carrier includes but not limited to: mannitol, sorbitol, sodium pyrosulfite, sulfurous
Acid hydrogen sodium, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, injection Vitamin B_6 DTA disodium, Ethylenediaminetetraacetic Acid Calcium Salt, monovalence
Alkali-metal carbonate, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, chlorination
Potassium, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol,
Silicon derivative, cellulose and its derivates, alginate, gelatin, polyvinylpyrrolidone, glycerol, POLYSORBATE 80, agar, calcium carbonate,
Calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, stearic acid
Calcium, magnesium stearate.
For realizing above-mentioned 3rd purpose, the present invention adopts the technical scheme that:
Application in the fat concurrent hyperlipidemia of arbitrary described Chinese medicine composition acupuncture and drugs preparation treatment, its
Middle acupuncture point selection, master point: the middle part of gastric cavity, Tianshu (double), rich and prosperous, Zhangmen, Gongsun, too white, gb 34, tsu san li, sp 9, three cloudy
Hand over.
Adjunct acupuncture points: bulimia substantially mixes gastral cavity, shou san li, Xiajuxu；Fu jie, Zhigou, Shangjuxu are joined in constipation；Amenorrhea or the moon
Paddy, Guan Yuan, dai channel, uterus, the sea of blood, sp 6 is coordinated through rareness；Edema mixes gastral cavity, moisture, Tianshu, Taiyuan, sp 9, the moon
Paddy, fuliu；Companion coronary disease patient joins interior pass, Danzhong, sp 6；Companion glycosuria patient joins Yang Chi, tsu san li, sp 6.
Operational approach: advise patient first to take dorsal position, by the middle part of gastric cavity, Tianshu (double), rich and prosperous, Zhangmen, Gongsun, too white, gb 34,
After the routine disinfection of tsu san li, sp 9, sp 6 each cave, selecting the 0.3mm*40mm disposable acupuncture needle of good strong board, inserting needle is brought about the desired sensation
After, imposing and put forward slotting twisted uniform reinforcing-reducing method, patient has the sour sense of numbness and distention for degree, connects the treatment of G6805-2A type low-frequency electronic pulse
Instrument.Acusector connects 2～4 groups of acupuncture points every time, and neighbouring same side joint is one group, selects dilatational wave, and frequency is 4, and current intensity is to suffer from
Person's tolerance is degree.Stimulation time 30min.ADT 1 time, continued treatment 3 months.
The invention has the advantages that:
1, the Chinese medicine composition of present invention hyperlipemia concurrent for obesity Splenic asthenia and obstruction of dampness patient has Weight-reducing and lipid-lowering
Double effect.
2, the proportioning of Chinese medicine composition of the present invention is obtained by great many of experiments screening, has good effect, effect more aobvious
The advantage write.
3, the fat concurrent high fat for the treatment of based on the Chinese medicine composition acupuncture and drugs group of the present invention can significantly improve acupuncture
The therapeutic effect of mass formed by blood stasis Splenic asthenia and obstruction of dampness, and the sings and symptoms of patient can be significantly improved.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate this
Bright rather than limit the scope of the present invention.In addition, it is to be understood that after having read the content that the present invention records, art technology
The present invention can be made various changes or modifications by personnel, and these equivalent form of values fall within the application appended claims equally and limited
Fixed scope.
Embodiment 1 treats the preparation () of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 25 parts, Radix Stephaniae Tetrandrae 10 parts, Rhizoma Atractylodis 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, 15 parts of Poria, Rhizoma Alismatis 15 parts, Semen Plantaginis 20 parts, Ramulus Cinnamomi
20 parts, 5 parts of Radix Glycyrrhizae, Semen Raphani 15 parts, Fructus Crataegi 15 parts, Semen Cassiae 10 parts, conventionally decoct.
Embodiment 2 treats the preparation (two) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 20 parts, Radix Stephaniae Tetrandrae 5 parts, Rhizoma Atractylodis 5 parts, the Rhizoma Atractylodis Macrocephalae 5 parts, 10 parts of Poria, Rhizoma Alismatis 10 parts, Semen Plantaginis 15 parts, Ramulus Cinnamomi 15
Part, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 3 treats the preparation (three) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 5 parts, Rhizoma Atractylodis 5 parts, the Rhizoma Atractylodis Macrocephalae 5 parts, 10 parts of Poria, Rhizoma Alismatis 10 parts, Semen Plantaginis 15 parts, Ramulus Cinnamomi 15
Part, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 4 treats the preparation (four) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 5 parts, the Rhizoma Atractylodis Macrocephalae 5 parts, 10 parts of Poria, Rhizoma Alismatis 10 parts, Semen Plantaginis 15 parts, Ramulus Cinnamomi 15
Part, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 5 treats the preparation (five) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 5 parts, 10 parts of Poria, Rhizoma Alismatis 10 parts, Semen Plantaginis 15 parts, Ramulus Cinnamomi
15 parts, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 6 treats the preparation (six) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 10 parts of Poria, Rhizoma Alismatis 10 parts, Semen Plantaginis 15 parts, Ramulus Cinnamomi
15 parts, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 7 treats the preparation (seven) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 10 parts, Semen Plantaginis 15 parts, Ramulus Cinnamomi
15 parts, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 8 treats the preparation (eight) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 20 parts, Semen Plantaginis 15 parts, Ramulus Cinnamomi
15 parts, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 9 treats the preparation (nine) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 20 parts, Semen Plantaginis 25 parts, Ramulus Cinnamomi
15 parts, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 10 treats the preparation (ten) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 20 parts, Semen Plantaginis 25 parts, Ramulus Cinnamomi
25 parts, 1 part of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 11 treats the preparation (11) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 20 parts, Semen Plantaginis 25 parts, Ramulus Cinnamomi
25 parts, 10 parts of Radix Glycyrrhizae, Semen Raphani 10 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 12 treats the preparation (12) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 20 parts, Semen Plantaginis 25 parts, Ramulus Cinnamomi
25 parts, 10 parts of Radix Glycyrrhizae, Semen Raphani 20 parts, Fructus Crataegi 10 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 13 treats the preparation (13) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 20 parts, Semen Plantaginis 25 parts, Ramulus Cinnamomi
25 parts, 10 parts of Radix Glycyrrhizae, Semen Raphani 20 parts, Fructus Crataegi 20 parts, Semen Cassiae 5 parts, conventionally decoct.
Embodiment 14 treats the preparation (14) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 30 parts, Radix Stephaniae Tetrandrae 15 parts, Rhizoma Atractylodis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, 20 parts of Poria, Rhizoma Alismatis 20 parts, Semen Plantaginis 25 parts, Ramulus Cinnamomi
25 parts, 10 parts of Radix Glycyrrhizae, Semen Raphani 20 parts, Fructus Crataegi 20 parts, Semen Cassiae 15 parts, conventionally decoct.
Embodiment 15 treats the preparation (15) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 22 parts, Radix Stephaniae Tetrandrae 7 parts, Rhizoma Atractylodis 7 parts, the Rhizoma Atractylodis Macrocephalae 7 parts, 13 parts of Poria, Rhizoma Alismatis 13 parts, Semen Plantaginis 17 parts, Ramulus Cinnamomi 17
Part, 3 parts of Radix Glycyrrhizae, Semen Raphani 13 parts, Fructus Crataegi 13 parts, Semen Cassiae 7 parts, conventionally decoct.
Embodiment 16 treats the preparation (16) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 28 parts, Radix Stephaniae Tetrandrae 13 parts, Rhizoma Atractylodis 7 parts, the Rhizoma Atractylodis Macrocephalae 7 parts, 13 parts of Poria, Rhizoma Alismatis 13 parts, Semen Plantaginis 17 parts, Ramulus Cinnamomi 17
Part, 3 parts of Radix Glycyrrhizae, Semen Raphani 13 parts, Fructus Crataegi 13 parts, Semen Cassiae 7 parts, conventionally decoct.
Embodiment 17 treats the preparation (17) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 28 parts, Radix Stephaniae Tetrandrae 13 parts, Rhizoma Atractylodis 13 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, 13 parts of Poria, Rhizoma Alismatis 13 parts, Semen Plantaginis 17 parts, Ramulus Cinnamomi
17 parts, 3 parts of Radix Glycyrrhizae, Semen Raphani 13 parts, Fructus Crataegi 13 parts, Semen Cassiae 7 parts, conventionally decoct.
Embodiment 18 treats the preparation (18) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 28 parts, Radix Stephaniae Tetrandrae 13 parts, Rhizoma Atractylodis 13 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, 17 parts of Poria, Rhizoma Alismatis 17 parts, Semen Plantaginis 17 parts, Ramulus Cinnamomi
17 parts, 3 parts of Radix Glycyrrhizae, Semen Raphani 13 parts, Fructus Crataegi 13 parts, Semen Cassiae 7 parts, conventionally decoct.
Embodiment 19 treats the preparation (19) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 28 parts, Radix Stephaniae Tetrandrae 13 parts, Rhizoma Atractylodis 13 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, 17 parts of Poria, Rhizoma Alismatis 17 parts, Semen Plantaginis 23 parts, Ramulus Cinnamomi
23 parts, 3 parts of Radix Glycyrrhizae, Semen Raphani 13 parts, Fructus Crataegi 13 parts, Semen Cassiae 7 parts, conventionally decoct.
Embodiment 20 treats the preparation (20) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 28 parts, Radix Stephaniae Tetrandrae 13 parts, Rhizoma Atractylodis 13 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, 17 parts of Poria, Rhizoma Alismatis 17 parts, Semen Plantaginis 23 parts, Ramulus Cinnamomi
23 parts, 7 parts of Radix Glycyrrhizae, Semen Raphani 17 parts, Fructus Crataegi 13 parts, Semen Cassiae 7 parts, conventionally decoct.
Embodiment 21 treats the preparation (21) of the Chinese medicine composition of fat concurrent hyperlipemia
The Radix Astragali 28 parts, Radix Stephaniae Tetrandrae 13 parts, Rhizoma Atractylodis 13 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, 17 parts of Poria, Rhizoma Alismatis 17 parts, Semen Plantaginis 23 parts, Ramulus Cinnamomi
23 parts, 7 parts of Radix Glycyrrhizae, Semen Raphani 17 parts, Fructus Crataegi 17 parts, Semen Cassiae 13 parts, conventionally decoct.
It should be noted that the conventional method decoction described in embodiment 1-21 is the manufacture method of Chinese medicine decoction routine, i.e.
Described crude drug boiling is become decoction.
Embodiment 22 treats the preparation of fat concurrent hyperlipidemia tablets/capsules
The arbitrary described medicine of Example 1-21, adds 8-12 times amount water, decocts 1-3 hour, leach medicine juice.Add 10 times again
Amount water, decocts 1.5-2.5 hour, leaches medicine juice, merges secondary decocting liquid, stands, leaching supernatant, concentrates, lets cool, add concentrated solution
2.5 times amount ethanol, stir precipitates overnight.Take supernatant, be concentrated into thick extractum；Add pharmaceutical aids, vacuum drying, pulverize system
Grain, is pressed into tablet or fills encapsulated.
Embodiment 23 treats the preparation of fat concurrent hyperlipidemia granule
The arbitrary described medicine of Example 1-21, adds 8-10 times amount water, decocts 2.5-3.5 hour, leach medicine juice.Add again
10 times amount water, decoct 2 hours, leach medicine juice, merge secondary decocting liquid, stand, leaching supernatant, concentrate, let cool, add concentrated solution 2
Times amount ethanol, stirs precipitates overnight.Take supernatant, be concentrated into thick extractum；Add suitable pharmaceutical aids, pelletize, be dried, granulate,
20g granule, subpackage 10g/ bag.
Embodiment 24 treats the preparation of fat concurrent hyperlipidemia mixture/oral liquid/syrup
The arbitrary described medicine of Example 1-21, adds 8-10 times amount water, decocts 3 hours, leach medicine juice.Add 8 times amount again
Water, decocts 2 hours, leaches medicine juice, merges secondary decocting liquid, stands, leaching supernatant, concentrates, lets cool, add concentrated solution 2 times amount wine
Essence, stirs precipitates overnight.Take supernatant, be concentrated into thick extractum；Add suitable pharmaceutical aids, make mixture, oral liquid or syrup.
Embodiment 25 treats the clinical trial of fat concurrent hyperlipidemia curative effect
1 material and method
1.1 material
Include the fat concurrent hyperlipidemia patient of Splenic asthenia and obstruction of dampness that 200 examples are gone to a doctor from hospital clinic in, use random
Digits table is divided into treatment one group, treats two groups, treats three groups, matched group, minimum 23 years old for the treatment of group age, maximum 66 years old, flat
Equal 39.52 ± 11.25 years old；The fat course of disease the shortest half a year, the longest 55 years, average 19.33 ± 15.84 years.Matched group minimal ages
19 years old, maximum 59 years old, average 34.47 ± 11.82 years old；The fat course of disease the shortest half a year, the longest 57 years, average 18.95 ± 14.74
Year.Four groups of ages, sex, the course of disease are similar, have comparability.
1.2 diagnostic criteria
With reference to obesity and the diagnostic criteria of hyperlipoproteinemia in " practical internal medicine ": (1) meets simple obesity
Diagnostic criteria；(2) Anomalous lipid metablism occurs and meets the diagnostic criteria of hyperlipemia albumen disease；(3) hyperlipemia diagnostic criteria:
Under normal diet, detection fasting 12h above daystart extracting vein blood is standard.Serum total cholesterol (TC) >=5.20mmol/L,
Triglyceride (TG) >=1.70mmol/L, low density lipoprotein, LDL (LDL-C) >=3.12mmol/L, high density lipoprotein (HDL-C)
≤1.04mmol/L.Tcm diagnosis standard: with reference to " acupuncture and moxibustion therapy of obesity ", formulates fat concurrent hyperlipemia spleen asthenia and dampness retention
Type, disease sees: obesity is with hyperlipidemia, anorexia, abdominal distention, loose stool, oliguria, fatigue and weak, the tired weight of limbs, lower limbs edema, female
Property opsomenorrhea, amount is few, and matter is dilute, and color is light, menstrual period or through after abdomen dull pain, profuse leukorrhea, in vain, matter is dilute for color；Light red tongue, greasy fur, soft pulse
Or it is slow.
1.3 inclusive criterias:
(1) meeting Western medicine diagnose standard, Chinese medical discrimination belongs to Splenic asthenia and obstruction of dampness；
(2) age 16-66 year；
(3) fat-reducing and blood fat reducing associated treatment are not carried out；
(4) it is ready to study, and signs Informed Consent Form.
1.4 exclusion standard
(1) age is below 16 one full year of life or 65 one full year of life above person；
(2) other treatment measure has been accepted, it is possible to affect the treatment the observer judged；
(3) there are the complications such as severe cardiac, liver, kidney；
(4) other severe primary disease patient it is associated with；
(5) gestation or women breast-feeding their children；
(6) psychiatric patient.
1.5 Therapeutic Method
1.5.1 acupuncture and moxibustion therapy
Master point: the middle part of gastric cavity, Tianshu (double), rich and prosperous, Zhangmen, Gongsun, too white, gb 34, tsu san li, sp 9, sp 6.
Adjunct acupuncture points: bulimia substantially mixes gastral cavity, shou san li, Xiajuxu；Fu jie, Zhigou, Shangjuxu are joined in constipation；Amenorrhea or the moon
Paddy, Guan Yuan, dai channel, uterus, the sea of blood, sp 6 is coordinated through rareness；Edema mixes gastral cavity, moisture, Tianshu, Taiyuan, sp 9, the moon
Paddy, fuliu；Companion coronary disease patient joins interior pass, Danzhong, sp 6；Companion glycosuria patient joins Yang Chi, tsu san li, sp 6.
Operational approach: advise patient first to take dorsal position, by the middle part of gastric cavity, Tianshu (double), rich and prosperous, Zhangmen, Gongsun, too white, gb 34,
After the routine disinfection of tsu san li, sp 9, sp 6 each cave, selecting the 0.3mm*40mm disposable acupuncture needle of good strong board, inserting needle is brought about the desired sensation
After, imposing and put forward slotting twisted uniform reinforcing-reducing method, patient has the sour sense of numbness and distention for degree, connects the treatment of G6805-2A type low-frequency electronic pulse
Instrument.Acusector connects 2～4 groups of acupuncture points every time, and neighbouring same side joint is one group, selects dilatational wave, and frequency is 4, and current intensity is to suffer from
Person's tolerance is degree.Stimulation time 30min.ADT 1 time, continued treatment 3 months.Blood fat reducing and fat-reducing is all disabled during treatment
Medicine.
1.5.2 treatment by Chinese herbs
Treatment group gives acupuncture and medication in combination.One group of patient of Chinese medicine takes the medicine prepared by embodiment 1, decocts to concentration
For containing crude drug amount 0.22g/mL, every day 1 dose, 1 dose is 10mL.Two groups of patients of Chinese medicine take the medicine prepared by embodiment 5, decoct
It is that 1 dose is 10mL containing crude drug amount 0.22g/mL, every day 1 dose to concentration.Three groups of patients of Chinese medicine take Chinese medicine composition as described below
The medicine of preparation: the Radix Astragali 25 parts, Radix Stephaniae Tetrandrae 10 parts, Rhizoma Atractylodis 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, 15 parts of Poria, Rhizoma Alismatis 15 parts, Ramulus Cinnamomi 20 parts, sweet
Grass 5 parts, Semen Raphani 15 parts, Fructus Crataegi 15 parts, Semen Cassiae 10 parts, decoct to concentration be containing crude drug amount 0.22g/mL, every day 1 dose, 1
Agent is 10mL.Matched group patient gives simple acupuncture treatment.Four groups of patient's equal days treat 1 time, continued treatment three months.
2 observation of curative effect
2.1 observation index and method
Four groups of patients extract limosis vein blood 5mL morning 8 before treatment and after treatment 3 months.
(1) obesity index: measure four groups of Patient height, weight, stratum corneum lipids with reference to " acupuncture and moxibustion therapy of obesity ", and
Calculate constitutional index (BMI), body constitution percentage rate (F%), bluntness (A%).
(2) blood lipids index: measure T-CHOL (TC), triacylglycerol (TG), high density lipoprotein (HDL-C) and low-density
The content of lipoprotein (LDI-C).
2.2 efficacy assessment standard
With reference to " guideline of clinical investigations of new Chinese medicine treatment hyperlipemia " evaluation fat-reducing and the comprehensive therapeutic effect of blood fat reducing.
Clinical recovery: clinical symptom disappearance after treatment, weight decline reaches normal or overweight level, women F% ＜ 30%, male
F% ＜ 20%, and lipids detection reply is normal；Effective: clinical symptoms major part disappears, F% declines >=5%, and weight declines
>=5%, and lipids detection reach following any one person: TC decline >=20%, TG decline >=40%, HDL-C rise >=
0.26mmol/L；Effective: clinical symptoms substantially alleviates, F% >=3%, and ＜ 5%, weight decline >=3kg, and ＜ 5kg, and
Lipids detection reaches following any one person: TC decline >=10% but ＜ 20%, TG decline >=20% but ＜ 40%, HDL-C rising
>=0.104mmol/L but ＜ 0.26mmol/L；Invalid clinical symptoms is without significant change, and F% declines ＜ 3%, and weight declines ＜
3kg, and lipids detection is not up to above standard.
2.3 therapeutic outcome
(1) four group of patient clinical comparitive study
1 four groups of patients's comparitive study example (%) of table
| Group | n | Recovery from illness | Effective | Effectively | Invalid | Total effective rate |
| Treat one group | 50 | 16 | 25 | 9 | 0 | 50 (100.0%) * |
| Treat two groups | 50 | 3 | 28 | 17 | 2 | 48 (96.0%) * |
| Treat three groups | 50 | 3 | 19 | 22 | 6 | 44 (88.0%) |
| Matched group | 50 | 1 | 17 | 20 | 12 | 38 (76.0%) |
Note: compare * P < 0.05 with matched group.
Result is as shown in table 1, and matched group total effective rate is 76.0%, and treating one group of total effective rate is 100.0%, treats two
Group total effective rate is 96.0%, treats one group, treats two groups of total effective rates and compare with matched group, difference statistically significant (P <
0.01), show that treatment group curative effect is better than matched group.
Before and after (2) four groups of patient treatments, obesity index compares
Before and after 2 four groups of patient treatments of table, obesity index compares
Note: compare #P < 0.05 with before treatment；* P < 0.05 is compared with after treatment of control group.
Result is as shown in table 2, and four groups all have preferable curative effect on obesity, and the weight of patient, Rate of body lipid, BMI pass through
Substantially return fall (P < 0.05) after treatment, after above-mentioned four kinds of methods treatment is described, all have significant blood fat reducing loss of weight curative effect.Treat one group
Obesity index every with after treatment of control group compares, and difference has statistical significance (P < 0.05), shows to treat the curative effect of a group
It is better than matched group.
Before and after (3) four groups of patient treatments, blood fat compares
Before and after 3 four groups of patient treatments of table, blood fat compares
Note: compare #P < 0.05 with before treatment；* P < 0.05 is compared with after treatment of control group.
Result is as shown in table 3, and after treatment group and matched group patient treatment, TC, TG, LDL-C the most substantially return fall, and HDL-C
Rebound significantly, all has significant Bloodlipid-lowering after above-mentioned four kinds of methods treatment is described.Treat one group with treatment of control group after every
Blood lipids index compares, and difference has statistical significance (P < 0.5), illustrates that one group of acupuncture and medication in combination for the treatment of is every at recovery blood fat
In index, effect is more significantly.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of without departing from the inventive method, it is also possible to makes some improvement and supplements, and these improve and supplement and also should be regarded as
Protection scope of the present invention.
Claims (9)
1. the Chinese medicine composition treating fat concurrent hyperlipemia, it is characterised in that described Chinese medicine composition is by following
The crude drug of weight portion is made: Radix Astragali 20-30 part, Radix Stephaniae Tetrandrae 5-15 part, Rhizoma Atractylodis 5-15 part, Rhizoma Atractylodis Macrocephalae 5-15 part, Poria 10-20 part,
Rhizoma Alismatis 10-20 part, Semen Plantaginis 15-25 part, Ramulus Cinnamomi 15-25 part, Radix Glycyrrhizae 1-10 part, Semen Raphani 10-20 part, Fructus Crataegi 10-20 part,
Semen Cassiae 5-15 part.
The Chinese medicine composition of the fat concurrent hyperlipemia for the treatment of the most according to claim 1, it is characterised in that described Chinese drug-treated group
Compound is made up of the crude drug of following weight portion: Radix Astragali 22-28 part, Radix Stephaniae Tetrandrae 7-13 part, Rhizoma Atractylodis 7-13 part, Rhizoma Atractylodis Macrocephalae 7-13 part,
Poria 13-17 part, Rhizoma Alismatis 13-17 part, Semen Plantaginis 17-23 part, Ramulus Cinnamomi 17-23 part, Radix Glycyrrhizae 3-7 part, Semen Raphani 13-17 part, life
Fructus Crataegi 13-17 part, Semen Cassiae 7-13 part.
The Chinese medicine composition of the fat concurrent hyperlipemia for the treatment of the most according to claim 1, it is characterised in that described Chinese drug-treated group
Compound is made up of the crude drug of following weight portion: the Radix Astragali 25 parts, Radix Stephaniae Tetrandrae 10 parts, Rhizoma Atractylodis 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, 15 parts of Poria,
Rhizoma Alismatis 15 parts, Semen Plantaginis 20 parts, Ramulus Cinnamomi 20 parts, 5 parts of Radix Glycyrrhizae, Semen Raphani 15 parts, Fructus Crataegi 15 parts, Semen Cassiae 10 parts.
4. the purposes of the arbitrary described Chinese medicine composition of claim 1-3, it is characterised in that be used for preparing the fat concurrent high fat for the treatment of
Application in the medicine of mass formed by blood stasis.
Purposes the most according to claim 4, it is characterised in that described fat Chinese medical discrimination belongs to Splenic asthenia and obstruction of dampness.
Purposes the most according to claim 4, it is characterised in that described medicine adds pharmaceutically acceptable carrier as required
It is prepared as any pharmaceutical dosage form.
Purposes the most according to claim 4, it is characterised in that described medicine also includes the adjuvant pharmaceutically allowed.
Purposes the most according to claim 4, it is characterised in that the dosage form of described medicine is capsule, granule, tablet, is administered orally
Liquid, mixture or syrup.
9. answering in the fat concurrent hyperlipidemia of claim 1-3 arbitrary described Chinese medicine composition acupuncture and drugs preparation treatment
It is the middle part of gastric cavity, Tianshu (double), rich and prosperous, Zhangmen, Gongsun, too white, gb 34, tsu san li, cloudy mound with, it is characterised in that acupuncture point selection
Spring, sp 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610950646.5A CN106266334A (en) | 2016-10-27 | 2016-10-27 | A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610950646.5A CN106266334A (en) | 2016-10-27 | 2016-10-27 | A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106266334A true CN106266334A (en) | 2017-01-04 |
Family
ID=57719919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610950646.5A Pending CN106266334A (en) | 2016-10-27 | 2016-10-27 | A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106266334A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116440221A (en) * | 2023-05-12 | 2023-07-18 | 云南润苍生科技有限公司 | Compound weight-losing product containing white kidney beans and preparation method and application thereof |
-
2016
- 2016-10-27 CN CN201610950646.5A patent/CN106266334A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| 冯建华等: "《内分泌与代谢病的中医治疗》", 30 September 2001, 人民卫生出版社 * |
| 刘志诚: "《肥胖病的针灸治疗》", 1 July 2008, 人民卫生出版社 * |
| 王鸣等: ""温针灸联合耳针治疗脾虚湿阻型肥胖并发高脂血症患者临床疗效"", 《世界华人消化杂志》 * |
| 邢宁等: ""单纯性肥胖症的中医治疗"", 《时珍国医国药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116440221A (en) * | 2023-05-12 | 2023-07-18 | 云南润苍生科技有限公司 | Compound weight-losing product containing white kidney beans and preparation method and application thereof |
| CN116440221B (en) * | 2023-05-12 | 2024-03-26 | 云南润苍生科技有限公司 | Compound weight-losing product containing white kidney beans and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN104399009A (en) | Traditional Chinese medicine formula for treating liver cancer and preparation method adopting traditional Chinese medicine formula | |
| CN101953936B (en) | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof | |
| CN104435837A (en) | Pharmaceutical composition for treating spontaneous perspiration and night sweat | |
| CN104069162A (en) | Traditional Chinese medicine for treating gouty arthritis and various bone and arthrosis pains | |
| CN104623583A (en) | Asthenia cold abdominalgia treating drug and preparation method of asthenia cold abdominalgia treating drug oral liquid | |
| Hijikata et al. | Kampo medicine, based on traditional medicine theory, in treating uncured glossodynia: efficacy in five clinical cases | |
| CN106266334A (en) | A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application | |
| CN103585449A (en) | Traditional Chinese medicine composition for treating migraine | |
| CN103920102A (en) | Traditional Chinese medicine for treating primary hypotension | |
| CN103055218A (en) | Traditional Chinese medicine composition for treating neonatal jaundice and preparation method thereof | |
| CN102580030A (en) | External traditional Chinese medicine composition having effect of reducing blood sugar, preparation prepared from the external traditional Chinese medicine composition, and their preparation method | |
| CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
| CN105727163A (en) | A traditional Chinese medicine formula for treating liver cancer and a preparing method thereof | |
| CN104689239A (en) | Traditional Chinese medicine composition for treating cholelithiasis and preparation method thereof | |
| CN103301403A (en) | Chinese medicine composition for treating pain in terminal cancers | |
| US11771727B2 (en) | Traditional Chinese medicine composition and product for improving sleep by balancing yin and yang, method for making the same and use thereof | |
| CN103463375B (en) | Traditional Chinese medicine composition for treating chronic type viral hepatitis B | |
| CN104740013A (en) | Traditional Chinese medicine composition for treating malignant tumors | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN105920409A (en) | Medicinal preparation for treating Alzheimer disease and application of medicinal preparation | |
| CN118987151A (en) | Traditional Chinese medicine formula of decoction for tonifying middle-jiao and rehmannia as well as preparation method and application thereof | |
| CN104491182A (en) | Traditional Chinese medicine for reducing side effects of chemotherapy and preparation method | |
| CN102178917B (en) | Chinese medicinal composition for treating qi channelling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |